NCT01919203

the Effective Bolus Dose of Remifentanil for Laryngeal Mask Airway (LMA) Insertion in Children

Name: Clinical Trial NCT01919203
Creator: Sangjin Park
Keywords: Respiratory Complication, Remifentanil, drug, clinical trial, South Korea

the Effective Bolus Dose of Remifentanil for Laryngeal Mask Airway (LMA) Insertion in Pediatric Patients

Sangjin Park·ClinicalTrials.gov·drugCompleted

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Respiratory Complication
Drug/Device/Intervention: Remifentanil
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Sangjin Park
Funder: Yeungnam University College of Medicine
Location: Nam gu, South Korea

Timeline & enrollment

Phase: N/A
Start date: Aug 01, 2013
End date: Jul 01, 2015
Enrollment: 50 participants

Primary outcome

patients's response to the LMA insertion

Summary

This research attempts to find the optimum dose of remifentanil that can prevent the unnecessary responses such as coughing, gagging, and movement when LMA is inserted during sevoflurane induction in pediatric patients.

ICD-10 classifications

Respiratory disorder, unspecifiedOther respiratory disordersRespiratory failure, unspecifiedOther postprocedural respiratory disordersOther specified respiratory disorders

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT01919203
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT01919203 through Pure Global AI's free database. This phase not specified trial is sponsored by Sangjin Park and is currently Completed. The study focuses on Respiratory Complication. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.